Clinical Trials Directory

Trials / Unknown

UnknownNCT05443815

Registry on the Use of HaemoCER-Plus in the Treatment and Prevention of Post-resectional Bleeding

Prospective Multicenter Registry on the Use of HaemoCer-PLUSPlus in the Treatment and Prevention of Post-resectional Bleeding

Status
Unknown
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
Istituto Clinico Humanitas Mater Domini · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Gastrointestinal bleeding is defined as clinical evidence of bleeding manifested by melena, hematochezia that required endoscopic hemostasis. GI bleeding associated to endoscopic procedure is defined as clinical evidence of bleeding and a drop in hemoglobin of ≥ 2g/dL on the day of the procedure (early bleeding) or up to 14 days after the procedure (delayed bleeding).GI bleeding is, nevertheless, a common complication of endoscopic procedures, such as endoscopic mucosal resection (EMR) and endoscopic sub mucosal dissection (ESD). For example, colorectal ESD, which is technically more difficult than gastric or esophageal ESD because of the anatomical features of the colon, present an increased risk of delayed bleeding. According to literature, early bleeding occurs on average in 5,3% of endoscopic resections of the whole digestive tract, with bleeding rates per location as follows: esophagus 9.4%, stomach 9.1%, duodenum 3.6%, colon 3.4%. Concerning delayed bleeding, it is assessed to complicate 3.1% of endoscopic resection procedures. The bleeding rate in the duodenum is usually the highest (6.3%), followed by colon at (3.6%), stomach (1.5%) and esophagus (0.9%). Age, lesion size and piecemeal resection are associated with an increased risk of bleeding. Usage of aspirin or NSAIDs seems to not increase risk of post-polypectomy bleeding, while clopidogrel and warfarin do and should be discontinued in the periprocedural period to prevent the occurrence of post-polypectomy bleeding. Direct oral anticoagulants (DOAC) administration shows similar post-procedural gastrointestinal bleeding risk to anti-vitamin K antagonists (VKA) administration in patients undergoing endoscopic procedures.

Conditions

Interventions

TypeNameDescription
DEVICEHaemoCer-PLUSHaemoCer-PLUS

Timeline

Start date
2022-07-01
Primary completion
2022-07-01
Completion
2023-07-30
First posted
2022-07-05
Last updated
2022-07-08

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05443815. Inclusion in this directory is not an endorsement.